These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12173972)

  • 21. Overview on AON design.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():117-29. PubMed ID: 22454058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
    Branch AD
    Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to antisense oligonucleotides by application of secondary structure predictions and RNase H in combination with MALDI-TOF mass spectrometry.
    Gabler A; Krebs S; Seichter D; Förster M
    Nucleic Acids Res; 2003 Aug; 31(15):e79. PubMed ID: 12888531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides.
    Gee JE; Robbins I; van der Laan AC; van Boom JH; Colombier C; Leng M; Raible AM; Nelson JS; Lebleu B
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):103-11. PubMed ID: 9593048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opportunities and challenges for antisense oligonucleotide therapies.
    Kuijper EC; Bergsma AJ; Pijnappel WWMP; Aartsma-Rus A
    J Inherit Metab Dis; 2021 Jan; 44(1):72-87. PubMed ID: 32391605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of bcl-xL expression by antisense oligonucleotides containing various bridged nucleic acids (BNAs).
    Roongjang S; Takahashi K; Obika S; Imanishi T
    Nucleic Acids Symp Ser (Oxf); 2007; (51):113-4. PubMed ID: 18029612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2'-Modified oligonucleotides for antisense therapeutics.
    Prakash TP; Bhat B
    Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.
    Yamamoto T; Fujii N; Yasuhara H; Wada S; Wada F; Shigesada N; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2014 Aug; 24(4):283-90. PubMed ID: 24758560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
    Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
    Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of 2',4'-propylene-bridged (carba-ENA) thymidine and its analogues: the engineering of electrostatic and steric effects at the bottom of the minor groove for nuclease and thermodynamic stabilities and elicitation of RNase H.
    Liu Y; Xu J; Karimiahmadabadi M; Zhou C; Chattopadhyaya J
    J Org Chem; 2010 Nov; 75(21):7112-28. PubMed ID: 20929200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation.
    Manoharan M
    Biochim Biophys Acta; 1999 Dec; 1489(1):117-30. PubMed ID: 10807002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis of cleavage by RNase H of hybrids of arabinonucleic acids and RNA.
    Minasov G; Teplova M; Nielsen P; Wengel J; Egli M
    Biochemistry; 2000 Apr; 39(13):3525-32. PubMed ID: 10736151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural, dynamic, and enzymatic properties of mixed alpha/beta-oligonucleotides containing polarity reversals.
    Germann MW; Aramini JM; Kalisch BW; van de Sande JH
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):493-9. PubMed ID: 11563065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
    Orum H; Wengel J
    Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of local mRNA structure on posttranscriptional gene silencing.
    Rudnick SI; Swaminathan J; Sumaroka M; Liebhaber S; Gewirtz AM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(37):13787-92. PubMed ID: 18784366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triazole- and Tetrazole-Bridged Nucleic Acids: Synthesis, Duplex Stability, Nuclease Resistance, and in Vitro and in Vivo Antisense Potency.
    Mitsuoka Y; Yamamoto T; Kugimiya A; Waki R; Wada F; Tahara S; Sawamura M; Noda M; Fujimura Y; Kato Y; Hari Y; Obika S
    J Org Chem; 2017 Jan; 82(1):12-24. PubMed ID: 27936689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids.
    Lima WF; Crooke ST
    Biochemistry; 1997 Jan; 36(2):390-8. PubMed ID: 9003192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The polypurine tract, PPT, of HIV as target for antisense and triple-helix-forming oligonucleotides.
    Volkmann S; Dannull J; Moelling K
    Biochimie; 1993; 75(1-2):71-8. PubMed ID: 7684936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2'β-Fluoro-Tricyclo Nucleic Acids (2'F-tc-ANA): Thermal Duplex Stability, Structural Studies, and RNase H Activation.
    Istrate A; Katolik A; Istrate A; Leumann CJ
    Chemistry; 2017 Aug; 23(43):10310-10318. PubMed ID: 28477335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.